Moderna is trading $170.63 (+10.77%) after announcing on September 21, 2026, that Phase 3 melanoma-vaccine data for intismeran autogene will receive a Presidential Symposium presentation at the October ESMO Congress.
- Investors viewed the prominent slot as a signal of potentially practice-changing results, although no new efficacy data was released.
- Company-specific oncology catalyst is driving the outsized move.
- Broader risk-on sentiment, falling oil prices, lower yields, and higher equities are reinforcing positive momentum.